Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: helospectin I
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang
Email: enquiry@dycnchem.com

93438-37-0

93438-37-0 structure

Name: helospectin I
Chemical Name: (4S)-5-[[(1S)-2-[[(1S)-2-[[(1S)-5-amino-1-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-5-amino-1-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-4-amino-1-[[(1S)-5-amino-1-[[(1S)-2-[[(1S)-1-[[(1S)-3-carboxy-1-[[(1S)-2-[[(1S,2S)-1-[[(1S)-1-[[2-[[(1S)-2-[[(1S)-2-[[(1S,2R)-1-[[(1S)-2-[(2S)-2-[[(1S)-1-[(2S)-2-[(2S)-2-[[(1S)-2-[[(1S)-1-carboxy-2-hydroxy-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]-4-guanidino-butyl]carbamoyl]pyrrolidin-1-yl]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]-2-hydroxy-propyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]-2-methyl-butyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]propyl]carbamoyl]-3-methyl-butyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]pentyl]carbamoyl]-4-oxo-butyl]carbamoyl]-3-methyl-butyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]pentyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]pentyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-propanoyl]amino]-3-carboxy-propanoyl]amino]propanoyl]amino]-3-hydroxy-butanoyl]amino]-3-phenyl-propanoyl]amino]-3-hydroxy-butanoyl]amino]propanoyl]amino]-5-oxo-pentanoic acid
CAS Number: 93438-37-0
Molecular Formula: C₁₈₃H₂₉₃N₄₇O₅₉
Molecular Weight:
Catalog: Research Areas Cardiovascular Disease
Create Date: 2021-09-12 19:23:40
Modify Date: 2024-02-21 20:00:25
Helospectin I is a neuropeptide of the vasoactive intestinal peptide (VIP) family. Helospectin I has vasodilatory and antihypertensive activities, and decreases blood pressure. Helospectin I is originally isolated from the salivary gland venom of the lizard Heloderma suspectum[1][2].

Name	(4S)-5-[[(1S)-2-[[(1S)-2-[[(1S)-5-amino-1-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-5-amino-1-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-4-amino-1-[[(1S)-5-amino-1-[[(1S)-2-[[(1S)-1-[[(1S)-3-carboxy-1-[[(1S)-2-[[(1S,2S)-1-[[(1S)-1-[[2-[[(1S)-2-[[(1S)-2-[[(1S,2R)-1-[[(1S)-2-[(2S)-2-[[(1S)-1-[(2S)-2-[(2S)-2-[[(1S)-2-[[(1S)-1-carboxy-2-hydroxy-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]-4-guanidino-butyl]carbamoyl]pyrrolidin-1-yl]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]-2-hydroxy-propyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]-2-methyl-butyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]propyl]carbamoyl]-3-methyl-butyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]pentyl]carbamoyl]-4-oxo-butyl]carbamoyl]-3-methyl-butyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]pentyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]pentyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-propanoyl]amino]-3-carboxy-propanoyl]amino]propanoyl]amino]-3-hydroxy-butanoyl]amino]-3-phenyl-propanoyl]amino]-3-hydroxy-butanoyl]amino]propanoyl]amino]-5-oxo-pentanoic acid

Description	Helospectin I is a neuropeptide of the vasoactive intestinal peptide (VIP) family. Helospectin I has vasodilatory and antihypertensive activities, and decreases blood pressure. Helospectin I is originally isolated from the salivary gland venom of the lizard Heloderma suspectum[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others
Target	Vasoactive intestinal peptide (VIP)[1]
In Vitro	Helospectin I (suffusion at 0.1 nM, in bicarbonate buffer for 30 min) evokes significant, sustained and similar vasodilation in the intact hamster cheek pouch[1]. Helospectin I relaxes the Phenylephrine-contracted rat femoral arteries with pEC50 of 6.82[2]. Helospectin I (0.1 nM-1 μM) inhibits the binding of 125I-labeled VIP and 125I-secretin to dispersed chief cells[4].
In Vivo	Helospectin I (0.03-2 nmol/kg, 100 μL of infusion at the left jugular vein) reduces blood pressure in rats[2]. Helospectin I (0.1-0.8 nmol /kg, i.v.) increases plasma levels of glucagon in mice[3]. Animal Model: SD rats[2] Dosage: 0.03, 0.3, 1, 2 nM/kg Administration: 100 μL of infusion at the left jugular vein, followed by washing the catheter with 100 μL saline. Result: Reduced the blood pressure, but was less effective than vasoactive intestinal peptide (VIP) in the low dose range. Animal Model: Mice[3] Dosage: 0.1, 0.2, 0.4, 0.8 nM /kg Administration: Intravenous injection (i.v.) Result: Markedly stimulated glucagon secretion, and had no direct action on insulin secretion.
References	[1]. Tsueshita T, et al. Helospectin I and II evoke vasodilation in the intact peripheral microcirculation. Peptides. 2004 Jan;25(1):65-9. [2]. Grundemar L, et al. Vascular effects of helodermin, helospectin I and helospectin II: a comparison with vasoactive intestinal peptide (VIP). Br J Pharmacol. 1990 Mar;99(3):526-8. [3]. Ahrén B. Effects of helospectin I on insulin and glucagon secretion in the mouse. Br J Pharmacol. 1991 Apr;102(4):916-8. [4]. Rai A, et al. Actions of Helodermatidae venom peptides and mammalian glucagon-like peptides on gastric chief cells. Am J Physiol. 1993 Jul;265(1 Pt 1):G118-25.

Molecular Formula	C₁₈₃H₂₉₃N₄₇O₅₉

93438-37-0	93585-83-2
141443-72-3	160219-88-5
412960-54-4	1346174-23-9
50939-54-3	849668-41-3
69150-58-9	12125-21-2
1396808-36-8	1396783-86-0
1396794-53-8	1396712-29-0
1396876-46-2	1396713-96-4
1396849-28-7	1396760-19-2
1396866-90-2	1448045-05-3